Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Rheumatoid Arthritis (RA Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

NCT07258849
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
LY4213663, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
9
States / cities
Anniston, Alabama • Phoenix, Arizona • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 20, 2026, 11:56 PM EDT
Recruiting Not applicable Interventional

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07524244
View directory record Official record
Conditions
Crohn's Disease (CD), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
Interventions
Carnivore (Lion) Diet, Ketogenic diet
Behavioral
Lead sponsor
Fuller Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 19, 2026, 6:21 AM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
Interventions
Long Term Safety Monitoring Procedures
Other
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 71 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
10
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 20, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional

Dose Response of Exercise for Arthritis Management

NCT06880653
View directory record Official record
Conditions
Arthritis, Fibromyalgia (FM), Gout, Lupus Erythematosus, Systemic, Osteoarthritis, Rheumatoid Arthritis (RA)
Interventions
DREAM Adaptive Intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 20, 2026, 2:14 AM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
View directory record Official record
Conditions
Dermatomyositis, Multiple Sclerosis, Myasthaenia Gravis, Refractory Lupus Nephritis, Rheumatoid Arthritis (RA), Stiff Person Syndrome, Systemic Sclerosis (SSc)
Interventions
KYV-101
Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 20, 2026, 10:24 AM EDT
Recruiting No phase listed Observational

The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study

NCT07315997
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Rheumatoid Arthritis (RA
Interventions
high sensitivity cardiac troponin
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced May 8, 2026, 3:56 AM EDT
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114
View directory record Official record
Conditions
IIM, Idiopathic Inflammatory Myopathies (IIMs), Myositis, Refractory Rheumatoid Arthritis (RA), Rheumatoid Arthritis (RA, Scleroderma, Sjogren Syndrome, Sjogrens Disease, Systemic Sclerosis (SSc)
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Covina, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced May 17, 2026, 5:53 AM EDT
Active, not recruiting Not applicable Interventional

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT07221890
View directory record Official record
Conditions
Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Psoriasis (PsO), Rheumatoid Arthritis (RA)
Interventions
Offered an academic detailing session, Standard-of-care outreach from the insurance plan
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
1,325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Louisville, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 2:23 AM EDT
Active, not recruiting No phase listed Observational

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

NCT03631225
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Vectra
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
La Mesa, California • Murrieta, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 8, 2026, 12:29 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults

NCT06614166
View directory record Official record
Conditions
Bone Density, Kinetics, Product Persistence in GI Tract, Rheumatoid Arthritis (RA)
Interventions
SBD111 Probiotic Medical Food, SBD121 Probiotic Medical Food
Other
Lead sponsor
Solarea Bio, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced May 20, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)

NCT06706999
View directory record Official record
Conditions
Arthritis, Rheumatoid (RA), Rheumatoid Arthritis (RA)
Interventions
PREVAIL model of care
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Apr 22, 2026, 6:13 AM EDT
Completed No phase listed Observational

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

NCT05421442
View directory record Official record
Conditions
Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced May 20, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Juvenile Dermatomyositis (JDM), Juvenile Idiopathic Arthritis (JIA), Multiple Sclerosis (MS), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Pemphigus Vulgaris, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions
Ad26.COV2.S, BNT162b2, BNT162b2, Bivalent, Continue IS (B cell depletion therapy), Continue IS (MMF or MPA), Continue IS (MTX), Moderna mRNA-1273, Moderna mRNA-1273, Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (B cell depletion therapy), Withhold IS (MMF or MPA), Withhold IS (MTX)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 20, 2026, 8:43 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ASP5094, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced May 19, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced May 14, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Placebo for upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced May 18, 2026, 1:01 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

NCT03410056
View directory record Official record
Conditions
Rheumatoid Arthritis RA
Interventions
Efavaleukin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
Anniston, Alabama • Torrance, California • Lansing, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced May 12, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

NCT03682705
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Elsubrutinib, Placebo for elsubrutinib, Placebo for upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
78
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced May 12, 2026, 4:00 AM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Axial Spondyloarthritis and Ankylosing Spondylitis, Crohn's Disease (CD), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA)
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced May 20, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Methotrexate (MTX), abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced May 7, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

NCT01618955
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
VIBEX MTX
Device
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced May 20, 2026, 1:19 PM EDT